Table 1 Patient baseline demographics and clinical characteristics
From: Trends in overall mortality among US veterans with primary myelofibrosis
Characteristic | Overall Population | < 2 Modified IPSS Risk Factors | ≥2 Modified IPSS Risk Factors | |||
|---|---|---|---|---|---|---|
Pre-RUX Approval (n = 193) | Post-RUX Approval (n = 974) | Pre-RUX Approval (n = 113) | Post-RUX Approval (n = 777) | Pre-RUX Approval (n = 80) | Post-RUX Approval (n = 197) | |
Age, y, mean (SD) | 71.2 (11.2) | 69.3 (11.4) | 67.1 (11.6) | 67.9 (11.9) | 77.1 (7.3) | 74.8 (7.0) |
 ≥ 65 y, n (%) | 140 (72.5) | 707 (72.6) | 62 (54.9) | 515 (66.3) | 78 (97.5) | 192 (97.5) |
Male, n (%) | 191 (99.0) | 925 (95.0) | 112 (99.1) | 731 (94.1) | 79 (98.8) | 194 (98.5) |
Race, n (%) | ||||||
 White | 114 (59.1) | 710 (72.9) | 69 (61.1) | 569 (73.2) | 45 (56.3) | 141 (71.6) |
 Black | 18 (9.3) | 176 (18.1) | 8 (7.1) | 136 (17.5) | 10 (12.5) | 40 (20.3) |
 Other | 61 (31.6) | 28 (2.9) | 36 (31.9) | 20 (2.6) | 25 (31.3) | 8 (4.1) |
 Unknown | 0 | 60 (6.2) | 0 | 52 (6.7) | 0 | 8 (4.1) |
Charlson Comorbidity Index, mean (SD) | 1.42 (1.99) | 1.49 (2.04) | 0.97 (1.64) | 1.29 (1.81) | 2.06 (2.25) | 2.29 (2.63) |
Hb measured, n (%) | 193 (100) | 908 (93.2) | 113 (100) | 714 (91.9) | 80 (100) | 194 (98.5) |
 Hb < 10 g/dL, n (%)a | 92 (47.7) | 173 (19.1) | 21 (18.6) | 22 (3.1) | 71 (88.8) | 151 (77.8) |
WBC count, n (%) | 193 (100) | 923 (94.8) | 113 (100) | 736 (94.7) | 80 (100) | 197 (100) |
 WBC > 25 × 109/L, n (%)a | 29 (15.0) | 84 (9.1) | 23 (20.4) | 6 (0.8) | 23 (28.8) | 78 (39.6) |
Allogeneic HCT, n (%) | 0 | 19 (2.0) | 0 | 14 (1.8) | 0 | 5 (2.5) |
Splenomegalyb (± 90 days of index) | 0 | 54 (5.5) | 0 | 30 (3.9) | 0 | 24 (12.2) |
RUX use, n (%) | – | 83 (8.5) | – | 39 (5.0) | – | 44 (22.3) |